Full Text View
Tabular View
No Study Results Posted
Related Studies
Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females
This study is enrolling participants by invitation only.
Study NCT01548118   Information provided by Shanghai Zerun Biotechnology Co.,Ltd

First Received on February 29, 2012.   Last Updated on March 5, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Human Papillomavirus
Interventions listed in this trial
HPV 16/18 vaccine, 0,5ml
Placebo control, 0.5ml
HPV 16/18 vaccine, 1.0ml
Placebo control, 1.0ml
Sponsors listed in this trial
Shanghai Zerun Biotechnology Co.,Ltd


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services